Norah Sadek

Icahn School of Medicine at Mount Sinai — United States

Medicine · Health Sciences

7h-index1.1kcitations42works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Telomeres, Telomerase, and Senescence(17), Immunotherapy and Immune Responses(13), CAR-T cell therapy research(12), Skin Protection and Aging(10), Cell death mechanisms and regulation(5)

Publications42 total

Racial and ethnical disparities in treatment outcomes in patients with advanced HCC who received first-line immunotherapy.
Journal of Clinical Oncology·2026
1308 Disease-free survival with neoadjuvant cemiplimab +/- stereotactic body radiation in resectable hepatocellular carcinoma
2025Open Access
Neoadjuvant immunotherapy of hepatocellular carcinoma: A single-institution experience at Mount Sinai.
Journal of Clinical Oncology·2025
Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis
Journal of Clinical Medicine·2025· 1 citedOpen Access
P-408 Survival Analysis of Selinexor-Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Real-World Exploratory Analysis
Clinical Lymphoma Myeloma & Leukemia·2024· 2 cited
P-386 Effect of Prior Selinexor Exposure on Clinical Outcomes of Chimeric Antigen Receptor T-cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Descriptive Analysis
Clinical Lymphoma Myeloma & Leukemia·2024
Abstract 4090: Gut microbiota mimics as a source of cross-reactive tumor rejection antigens
Cancer Research·2024
CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review
Clinical Pharmacology & Therapeutics·2023· 13 cited
Data from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
2023Open Access
Supplementary Figures from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
2023Open Access
Data from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
2023Open Access
Supplementary Table S1 from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
2023Open Access
Supplementary Figures from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
2023Open Access
Supplementary Table S1 from A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
2023Open Access
Movie S2 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
2023Open Access
Movie S2 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
2023Open Access
Supplementary materials and methods from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
2023Open Access
Supplementary materials and methods from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
2023Open Access
Supplementary figures from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
2023Open Access
Movie S1 from Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Gao Zhang(25), Meenhard Herlyn(25), Giorgos C. Karakousis(24), Lynn M. Schuchter(24), Ravi K. Amaravadi(24), Clemens Krepler(24), Sergio Randell(24), Yiling Lu(24), Gordon B. Mills(24), Zhi Wei(24), Dennie T. Frederick(23), Chaoran Cheng(23), Lawrence W. Wu(23), Katrin Sproesser(23), Benchun Miao(23), Genevieve M. Boland(23), Keith T. Flaherty(23), Lawrence N. Kwong(22), Jiufeng Tan(22), Aurelie Beroard(22)